

**LSU HSC-New Orleans Institutional Biosafety Committee  
Meeting Minutes**

**Date:** Wednesday, March 11, 2026  
**Time:** 1:03PM-2:23PM  
**Location:** Zoom

**Members present:**

1. Zea, *IBC Chair*
2. Catling, *IBC Vice Chair*
3. Didier Mejia, *BSO*
4. Caro, *Animal Containment*
5. Aiyar
6. Baker
7. Curran, *Local Non-affiliated Member*
8. Guidry, *Local Non-affiliated Member*
9. Siggins
10. Wang
11. Yue
12. Zabaleta

**Members**

**excused:**

**Other Individuals**

1. Landry, *Research Compliance Analyst II, IBC/IACUC*

**Attendance:**

2. Fuselier, *Research Compliance Analyst II, IACUC/IBC*
3. Burkett, *Affiliated EH&S*
4. Constans, *Director ORS*

12:59pm **Quorum Present**

The IBC has 11 voting members and 6 are required to conduct business

1:03pm **Call to Order**

The IBC Chair called the meeting to order

1:04pm **Conflicts of Interest**

The IBC Chair reminded all members present to identify any conflicts of interest as each application is reviewed.

1:05pm **Review and approval of previous meeting minutes**

- January 14, 2026

A motion was made and seconded to approve the minutes as written. Motion carried.

These minutes were posted on the ORS IBC webpage.

1:06pm **Review of Prior Business**

- The committee welcomed Dr. Constans, Dr. Caro, and Dr. Baker. Updates to the IBC RMS were submitted on January 13, 2026.
- The committee reviewed the 2025 attendance records in accordance with the Attendance Policy

**Institutional Biosafety Committee**

- A Designated Member Review (DMR) policy was proposed to allow DMR for amendments involving significant changes and new protocols, except for those requiring Full Committee Review (FCR). The policy outlines that submission materials are distributed to all IBC members, who are provided two (2) business days to request FCR or submit comments. If FCR is not requested, the IBC Chairperson, or a qualified designee, may approve the amendment or protocol, require modifications to secure approval, or refer the amendment for FCR. Withholding approval is not an allowable outcome under DMR. Following discussion, the committee voted to approve the policy, and it has been posted on the IBC website.
- The committee was also informed of upcoming regional listening sessions regarding NIH efforts to modernize and strengthen biosafety oversight. On January 29, 2026, NIH and the Southern Biosafety Association (SBA) will co-host a virtual listening session, and members were encouraged to attend and participate in the policy development process. Registration details and event information were shared with the committee.

1:20pm **New Business**

- Addition of Virology Expertise to Committee  
The committee previously discussed the need to include a member with expertise in virology. Committee members are asked to submit names of potential candidates for consideration. Submitted candidates will be reviewed and presented to the committee for discussion and vote at a future meeting.

1:27pm **Review of Incidents & Non-compliance**

• **Administrative Closures Due to Inactivity from January 14, 2026 to March 11, 2026**

Title	Number	PI Name	Review Type	Continuing Review Date	Expiration Date
<a href="#">Role of DNA-PK in vascular inflammation**</a>	5482	Boulares, Abdel	Designated Member Review	September 28, 2025	September 28, 2028
<a href="#">Breeding of mice for research on vascular disease and cancer**</a>	5489	Boulares, Abdel	Designated Member Review	September 24, 2025	September 24, 2028
<a href="#">The Role of Mitochondrial Efficiency in NASH-Related HCC</a>	4837	Ronis, Martin	Designated Member Review	November 18, 2025	November 18, 2027
<a href="#">Non- Emergency treatment with CTL019/tisagenlecleucel/Kymriah®: Managed Access Program (MAP) to provide access to CTL019, for acute</a>	2471	Yu, Lolie	Designated Member Review	December 06, 2025	December 06, 2026

<a href="#">lymphoblastic leukemia (ALL) or large B-cell lymphoma patients with out of specification leukapheresis product and/or manuf</a>					
<a href="#">HIV-Associated Cancer Pathogenesis</a>	6375	Moaven, Omeed	Designated Member Review	December 07, 2025	December 07, 2028

*\*\*Protocols will be closed once DOD funds are transferred to Dr. Zabaleta*

• **Protocols that are suspended, in “Grace Period” and destined for administrative closure:**

Title	Number	PI Name	Review Type	Continuing Review Date	Expiration Date
<a href="#">Peptide-based PARP-1 inhibitors and replication deficient-oncolytic viruses as potential therapies against cancer</a>	5517	Boulares, Abdel	Full Committee	February 18, 2026	February 18, 2030
<a href="#">Nontuberculous Mycobacterium Clinical Database &amp; Biospecimen Bank</a>	5017	MacRae, Shelby	Designated Member Review	February 22, 2026	February 22, 2028
<a href="#">EFFECT OF CPR ON PERFUSION IN A PORCINE MODEL OF SEVERE HEMORRHAGIC SHOCK</a>	5674	Greiffenstein, Patrick	Designated Member Review	February 22, 2026	February 22, 2029
<a href="#">Breast Microenvironment Signaling during Cancer Initiation</a>	5188	Ochoa, Augusto	Designated Member Review	February 25, 2026	February 25, 2027

1:28pm **Inspections/Ongoing Oversight**

• **EH&S**

There were no updates or issues to report from EH&S at this time.

1:29pm **IBC Registrations & Amendments for Review**

- **Applications and amendments determined by the Chair or IBC Coordinator that do not fall under the NIH Guidelines for FCR**

- **New Protocols**

<b>IBC #10309</b>	<b>Generation and Functional Characterization of ATPase Enzymes</b>
<b>PI Name</b>	Buckley, Rebecca
<b>Project Overview</b>	<p>This project involves studying kinesin and related ATPase proteins to better understand how they function at the molecular level. Because full-length versions of these proteins are large and difficult to produce in sufficient quantities, smaller, non-functional fragments are generated for laboratory study. These fragments allow researchers to examine specific structural and functional components of the proteins in controlled experiments.</p> <p>The protein fragments are produced using standard laboratory bacterial expression systems. The gene segments used are modified for efficient production in bacteria and are not capable of independent replication or function outside of the experimental system.</p>

	The research uses established molecular biology and protein purification techniques and is conducted under standard biosafety practices. The overall goal is to improve understanding of ATPase protein mechanisms, including how they interact with other cellular components and respond to potential regulatory molecules.
<b>NIH Guidelines Section(s)</b>	III-F-8 Appx C-II
<b>Risk Assessment &amp; Discussion</b>	Personnel working in the laboratory will use appropriate personal protective equipment (PPE), including gloves, lab coats or disposable gowns, and chemical fume hood.
<b>Training</b>	All institutional trainings required are complete for lab staff listed in the registration: <ul style="list-style-type: none"> <li>• COI in Research</li> <li>• Laboratory Safety</li> <li>• IBC Compliance</li> <li>• BBP High Risk</li> <li>• Shipping Biological Materials</li> </ul>
<b>EH&amp;S Assessment</b>	The lab was inspected, and no deficiencies were found.
<b>Occupational Health Representative review (if applicable)</b>	N/A
<b>Biosafety Level Assignment</b>	BSL-1
<b>IRB status (if applicable)</b>	Application reviewed and approved
<b>IBC Vote</b>	The IBC determined that the application met all necessary requirements and was approved through designated member review (DMR). FCR was not required.
<b>IBC #10311</b>	<b>MicroRNAs as Key Regulators of Gene Expression in Skeletal Muscle of Children with Cerebral Palsy</b>
<b>PI Name</b>	Moreau, Noelle
<b>Project Overview</b>	Cerebral palsy (CP) is a neurological condition that does not worsen over time, but muscle weakness and stiffness often increase as children grow. Changes in muscle size, scarring, and reduced ability for muscle repair contribute to declining function. This pilot study will examine small molecules called muscle-enriched microRNAs (myomiRs), which help regulate genes involved in muscle growth and regeneration. Researchers will investigate whether these microRNAs are altered in children with CP and whether an intensive exercise program can improve their expression. The goal is to better understand the biological factors affecting muscle health in CP and explore how exercise may support muscle function.
<b>NIH Guidelines Section(s)</b>	N/A
<b>Risk Assessment &amp; Discussion</b>	Personnel working in the laboratory will use an appropriate chemical fume hood, BSL-2 Biosafety cabinet and will use personal protective equipment (PPE), including gloves, lab coats or disposable gowns, eye goggles, face shield, and surgical mask.
<b>Training</b>	All institutional trainings required are complete for lab staff listed in the registration: <ul style="list-style-type: none"> <li>• COI in Research</li> </ul>

	<ul style="list-style-type: none"> <li>• Laboratory Safety</li> <li>• IBC Compliance</li> <li>• BBP High Risk</li> </ul>
<b>EH&amp;S Assessment</b>	The lab was inspected, and no deficiencies were found.
<b>Occupational Health Representative review (if applicable)</b>	N/A
<b>Biosafety Level Assignment</b>	BSL-2
<b>IRB status (if applicable)</b>	Application Approved
<b>IBC Vote</b>	The IBC determined that the application met all necessary requirements and was approved through designated member review (DMR). FCR was not required.
<b>IBC #10366</b>	<b>Vascular Endothelial Response to Infection by Eukaryotic Pathogens</b>
<b>PI Name</b>	Johnston, Doug
<b>Project Overview</b>	This project focuses on two important disease-causing organisms: <i>Candida albicans</i> , a fungus responsible for serious infections worldwide, and <i>Trypanosoma cruzi</i> , the parasite that causes Chagas disease in parts of Latin America. Both infections lack effective vaccines and have limited treatment options, with increasing concerns about drug resistance. The research aims to identify new biological targets that could lead to improved therapies. Scientists will study how these organisms interact with host cells and will evaluate new antifungal compounds for their ability to inhibit the growth of <i>Candida</i> species. The goal is to support the development of more effective treatments for these infections.
<b>NIH Guidelines Section(s)</b>	N/A
<b>Risk Assessment &amp; Discussion</b>	Personnel working in the laboratory will use a BSL-2 Biosafety cabinet and will use personal protective equipment (PPE), including gloves and lab coats or disposable gowns.
<b>Training</b>	All institutional trainings required are complete for lab staff listed in the registration: <ul style="list-style-type: none"> <li>• COI in Research</li> <li>• Laboratory Safety</li> <li>• IBC Compliance</li> <li>• BBP High Risk</li> </ul>
<b>EH&amp;S Assessment</b>	The lab was inspected, and no deficiencies were found.
<b>Occupational Health Representative review (if applicable)</b>	N/A
<b>Biosafety Level Assignment</b>	BSL-2
<b>IACUC status (if applicable)</b>	N/A

<b>IBC Vote</b>	The IBC determined that the application met all necessary requirements and was approved through designated member review (DMR). FCR was not required.
<b>IBC #10413</b>	<b>Serotonin-Microglia Interaction in the Adult Mouse Brain</b>
<b>PI Name</b>	Klempin, Friederike
<b>Project Overview</b>	As people age, many develop problems with memory, mood, and metabolic health, such as high blood pressure. Serotonin is a brain chemical that helps regulate mood, thinking, and energy balance, and many antidepressants work by increasing serotonin levels. However, these medications do not help everyone, and scientists do not fully understand why. Recent research suggests that serotonin also affects microglia, the brain's immune cells. While microglia normally protect the brain, they can become overactive with aging or stress and cause harmful inflammation linked to memory loss and depression. This study will examine how serotonin influences brain cells under conditions such as exercise, antidepressant treatment, and high blood pressure. The goal is to better understand brain inflammation and identify new ways to improve treatment of mood and age-related brain disorders.
<b>NIH Guidelines Section(s)</b>	N/A
<b>Risk Assessment &amp; Discussion</b>	Personnel working in the laboratory will use a BSL-1 Biosafety cabinet and will use personal protective equipment (PPE), including gloves and lab coats or disposable gowns.
<b>Training</b>	All institutional trainings required are complete for lab staff listed in the registration: <ul style="list-style-type: none"> <li>• COI in Research</li> <li>• Laboratory Safety</li> <li>• IBC Compliance</li> <li>• BBP High Risk</li> <li>• Shipping Biological Materials</li> </ul>
<b>EH&amp;S Assessment</b>	The lab was inspected, and no deficiencies were found.
<b>Occupational Health Representative review (if applicable)</b>	N/A
<b>Biosafety Level Assignment</b>	BSL-1 ABSL-1
<b>IACUC status (if applicable)</b>	Application approved
<b>IBC Vote</b>	The IBC determined that the application met all necessary requirements and was approved through designated member review (DMR). FCR was not required.
<b>IBC #10370</b>	<b>Effect of Surface Texture on Shear Bond Strength of 3D Printed Orthodontic Brackets to Enamel</b>
<b>PI Name</b>	Nejat, Amir Hossein
<b>Project Overview</b>	This study evaluates the performance of 3D-printed orthodontic brackets with different surface textures to determine how well they bond to teeth. Extracted human teeth, which are disinfected and stored according to dental school guidelines, will be used for testing. The brackets will be produced using a dental 3D printer, bonded to the tooth surface, and later removed to measure bond strength. The results will help determine whether textured 3D-printed brackets could

	improve orthodontic treatment outcomes. All Environmental Health & Safety (EH&S) procedures for disinfection will be followed during the study.
<b>NIH Guidelines Section(s)</b>	N/A
<b>Risk Assessment &amp; Discussion</b>	Personnel working in the laboratory will use a BSL-1 Biosafety cabinet and will use personal protective equipment (PPE), including gloves and lab coats or disposable gowns.
<b>Training</b>	All institutional trainings required are complete for lab staff listed in the registration: <ul style="list-style-type: none"> <li>• COI in Research</li> <li>• Laboratory Safety</li> <li>• IBC Compliance</li> <li>• BBP High Risk</li> </ul>
<b>EH&amp;S Assessment</b>	The lab was inspected, and no deficiencies were found.
<b>Occupational Health Representative review (if applicable)</b>	N/A
<b>Biosafety Level Assignment</b>	BSL-1
<b>IACUC status (if applicable)</b>	N/A
<b>IBC Vote</b>	The IBC determined that the application met all necessary requirements and was approved through designated member review (DMR). FCR was not required.
<b>IBC #10378</b>	<b>Inter-organelle link between mitotic apparatus and endoplasmic reticulum: defining kinesin-viral protease interactions in disease models</b>
<b>PI Name</b>	Wojcik, Edward
<b>Project Overview</b>	Zika virus has emerged as a growing global health concern. The virus was first associated with neurodevelopmental defects, notably microcephaly in developing fetuses during pregnancy. The Zika virus possesses a specific protease called NS2B-NS3. This protease plays a crucial role in the virus's life cycle by cleaving the viral polyprotein into individual proteins. Our work aims to investigate how the NS2B-NS3 protease impacts host neuronal cell division. This investigation will utilize both cell culture systems and the Drosophila (fruit fly) animal model, which is commonly used in biological research.
<b>NIH Guidelines Section(s)</b>	N/A
<b>Risk Assessment &amp; Discussion</b>	Personnel working in the laboratory will use a BSL-2 Biosafety cabinet and will use personal protective equipment (PPE), including gloves and lab coats or disposable gowns.
<b>Training</b>	All institutional trainings required are complete for lab staff listed in the registration: <ul style="list-style-type: none"> <li>• COI in Research</li> <li>• Laboratory Safety</li> <li>• IBC Compliance</li> <li>• BBP High Risk</li> </ul>
<b>EH&amp;S Assessment</b>	The lab was inspected, and no deficiencies were found.

<b>Occupational Health Representative review (if applicable)</b>	N/A
<b>Biosafety Level Assignment</b>	BSL-2
<b>IACUC status (if applicable)</b>	Application approved
<b>IBC Vote</b>	The IBC determined that the application met all necessary requirements and was approved through designated member review (DMR). FCR was not required.
<b>IBC #10317</b>	<b>The Effects of Antimicrobial Surface Coatings on Biofilm Formation upon Titanium Discs</b>
<b>PI Name</b>	Ballard, Richard
<b>Project Overview</b>	Temporary anchorage devices (TADs) are small implants used in orthodontics to help guide tooth movement during treatment. However, inflammation and infection around the implant site can sometimes cause these devices to fail. This study will evaluate whether antimicrobial coatings applied to titanium surfaces can help reduce bacterial growth and biofilm formation. Researchers will compare titanium discs coated with copper, selenium nanoparticles, and silver-platinum to uncoated titanium discs to determine how well each coating prevents microbial buildup. The goal is to identify coatings that could reduce infection risk and improve the long-term success of orthodontic implants.
<b>NIH Guidelines Section(s)</b>	N/A
<b>Risk Assessment &amp; Discussion</b>	Personnel working in the laboratory will use a BSL-2 Biosafety cabinet and will use personal protective equipment (PPE), including gloves and lab coats or disposable gowns.
<b>Training</b>	All institutional trainings required are complete for lab staff listed in the registration: <ul style="list-style-type: none"> <li>• COI in Research</li> <li>• Laboratory Safety</li> <li>• IBC Compliance</li> <li>• BBP High Risk</li> </ul>
<b>EH&amp;S Assessment</b>	The lab was inspected, and no deficiencies were found.
<b>Occupational Health Representative review (if applicable)</b>	N/A
<b>Biosafety Level Assignment</b>	BSL-2
<b>IACUC status (if applicable)</b>	N/A
<b>IBC Vote</b>	The IBC determined that the application met all necessary requirements and was approved through designated member review (DMR). FCR was not required.
<b>IBC #10326</b>	<b>Impact of Moisture and Etching Protocol on the Shear Bond Strength of Orthodontic Brackets Using Etch-Free, Self-Etch, and Conventional Systems</b>

<b>PI Name</b>	Armbruster, Paul
<b>Project Overview</b>	This study evaluates different methods used to attach orthodontic brackets to teeth during braces treatment. When brackets come loose, treatment can be delayed and additional dental visits may be required. Researchers will compare the strength of three bonding approaches: the traditional etch-and-bond method, a self-etch primer, and a newer system designed to bond without the usual etching and rinsing steps. The study will test these methods under both dry conditions and conditions that simulate the presence of saliva. The goal is to determine whether newer bonding systems can perform as well as traditional techniques and improve reliability during orthodontic treatment.
<b>NIH Guidelines Section(s)</b>	N/A
<b>Risk Assessment &amp; Discussion</b>	Personnel working in the laboratory will use a BSL-2 Biosafety cabinet and will use personal protective equipment (PPE), including gloves and lab coats or disposable gowns.
<b>Training</b>	All institutional trainings required are complete for lab staff listed in the registration: <ul style="list-style-type: none"> <li>• COI in Research</li> <li>• Laboratory Safety</li> <li>• IBC Compliance</li> <li>• BBP High Risk</li> </ul>
<b>EH&amp;S Assessment</b>	The lab was inspected, and no deficiencies were found.
<b>Occupational Health Representative review (if applicable)</b>	N/A
<b>Biosafety Level Assignment</b>	BSL-2
<b>IACUC status (if applicable)</b>	N/A
<b>IBC Vote</b>	The IBC determined that the application met all necessary requirements and was approved through designated member review (DMR). FCR was not required.
<b>IBC #10393</b>	<b>Novel formulation of synthetic retinoid for chemoprevention</b>
<b>PI Name</b>	Shen, Qiang
<b>Project Overview</b>	Breast cancer is a disease not under full control. Despite major advances in detection and treatment of breast cancer over the last 20 years, far too many women still die of it. It is predicted that in 2020 more than 200,000 women will develop invasive breast cancer and more than 40,000 women will die of it in the United States alone. These statistics emphasize the urgent need to develop effective and safe agents for the prevention of this disease. Particularly, prevention of estrogen receptor (ER)-negative (ENBC) and triple-negative breast cancer (TNBC) constitutes a clinical obstacle that greatly impedes the effort to reduce breast cancer incidence and mortality. In fact, all ER-negative breast cancers and a significant portion of ER-positive breast cancers are not preventable using current preventive drugs. This research aims to develop a synthetic retinoid as a new cancer prevention therapy with high efficacy, low side effects, and achievable patient compliance for near-future translation.

Institutional Biosafety Committee

<b>NIH Guidelines Section(s)</b>	III-F-8 Appx C-VIII
<b>Risk Assessment &amp; Discussion</b>	Personnel working in the laboratory will use a BSL-1 Biosafety cabinet and will use personal protective equipment (PPE), including gloves, surgical mask, and lab coats or disposable gowns.
<b>Training</b>	All institutional trainings required are complete for lab staff listed in the registration: <ul style="list-style-type: none"> <li>• COI in Research</li> <li>• Laboratory Safety</li> <li>• IBC Compliance</li> <li>• BBP High Risk</li> </ul>
<b>EH&amp;S Assessment</b>	The lab was inspected, and no deficiencies were found.
<b>Occupational Health Representative review (if applicable)</b>	N/A
<b>Biosafety Level Assignment</b>	BSL-1 ABSL-1
<b>IACUC status (if applicable)</b>	Application approved
<b>IBC Vote</b>	The IBC determined that the application met all necessary requirements and was approved through designated member review (DMR). FCR was not required.
<b>IBC #10302</b>	<b>Cloning, expression, and biochemical testing of kinesin motors</b>
<b>PI Name</b>	Downs, Micquel
<b>Project Overview</b>	This project studies motor proteins and related enzymes called ATPases, which play important roles in cellular movement and energy use. To better understand how these proteins work, researchers produce and purify specific portions of the proteins using standard bacterial expression systems. Studying smaller functional regions allows scientists to perform detailed biochemical and biophysical experiments to examine how these enzymes function and interact with other cellular components. The research may also include testing how certain molecules influence ATPase activity. The overall goal is to improve understanding of protein mechanisms that are important for many biological processes and diseases.
<b>NIH Guidelines Section(s)</b>	III-E III-F-8 Appx C-II
<b>Risk Assessment &amp; Discussion</b>	Personnel working in the laboratory will use a BSL-2 Biosafety cabinet and will use personal protective equipment (PPE), including gloves, eye goggles, surgical mask, and lab coats or disposable gowns.
<b>Training</b>	All institutional trainings required are complete for lab staff listed in the registration: <ul style="list-style-type: none"> <li>• COI in Research</li> <li>• Laboratory Safety</li> <li>• IBC Compliance</li> <li>• BBP High Risk</li> <li>• Shipping Biological Materials</li> </ul>
<b>EH&amp;S Assessment</b>	The lab was inspected, and no deficiencies were found.

<b>Occupational Health Representative review (if applicable)</b>	N/A
<b>Biosafety Level Assignment</b>	BSL-2
<b>IACUC status (if applicable)</b>	N/A
<b>IBC Vote</b>	The IBC determined that the application met all necessary requirements and was approved through designated member review (DMR). FCR was not required.

- **Amendments and Renewals (January 15, 2026 to March 11, 2026)**

<b>Title</b>	<b>Number</b>	<b>PI Name</b>	<b>Submission Type</b>	<b>Expiration Date</b>	<b>Amendment Description</b>
<u>Targeting Glucose Metabolism with HJC0152 for Treating Metastatic Breast Cancer</u>	7695	Shen, Qiang	Amended	October 01, 2029	Addition of experimental material
<u>Targeting ADAM17 maturation in resistant hypertension</u>	2490	Lazartigues, Eric	Amended	November 15, 2026	Correction or clarification of protocol details
<u>Stereotactic injection of 6HODA and Preformed alpha-synuclein fibrils for Parkinson's model</u>	7462	Bazan, Nicolas	Amended	September 06, 2029	Change in study location
<u>Colony of Genetically engineered mice (Knock-out and transgenic) and Transgenic Rats for studies in brain and retinal injuries and diseases</u>	9343	Bazan, Nicolas	Amended	July 15, 2030	Change in personnel Change in study location
<u>Fungal-bacterial dynamics driving dysregulated host</u>	7265	Fidel, Paul	Amended	April 29, 2029	Change in study location

<u>responses and lethal synergism</u>					
<u>Role of host immune response and factors affecting resistance/susceptibility in the immunopathogenesis of Candida vaginitis</u>	7592	Fidel, Paul	Amended	July 27, 2029	Change in study location
<u>Louisiana Cancer Research Consortium: Biospecimen Core Laboratory</u>	2512	Zea, Arnold	Amended	August 06, 2026	Change in personnel
<u>Molecular mechanisms underlying alcohol consumption and reward</u>	6978	Maiya, Rajani	Amended	June 30, 2030	Change in personnel Change in funding source or sponsor
<u>Novel Neuroprotective lipid mediators for Ischemic Stroke</u>	4639	Bazan, Nicolas	Amended	November 01, 2027	Change in personnel
<u>Calcium channels in health and disease</u>	8497	Pathak, Trayambak	Amended	June 06, 2030	Change in personnel Change in study location/facilities
<u>Development of Vapor Inhalation Chambers for Drug Self-Administration in Rodents</u>	4887	Gilpin, Nicholas	Amended	December 08, 2027	Change in personnel
<u>Role of alpha2 adrenergic receptor antagonism in treating misuse of fentanyl adulterated with xylazine</u>	9419	Pahng, Amanda	Amended	August 18, 2030	Change in personnel Change in study location/facilities

<u>Role of Neuropeptides in Stress-Induced Escalation of Alcohol Drinking</u>	4457	Gilpin, Nicholas	Amended	August 15, 2027	Change in personnel
<u>Neuropeptide studies</u>	2563	Whim, Matthew	Amended	May 19, 2026	Addition of experimental material
<u>ADHD and the influence of adolescent alcohol consumption on cognition and behavior</u>	7627	Salling, Michael	Amended	October 14, 2029	Change in Personnel
<u>Synaptic, dendritic and neural plasticity mechanisms</u>	9969	Middleton, Jason	Amended	October 16, 2030	Change in Personnel
<u>Sex Specific Effects of Adolescent Alcohol Exposure on BNST Plasticity</u>	10041	Wills, Tiffany	Amended	November 24, 2030	Change in Personnel
<u>Synaptic Transmission in Cerebellum, Cellular Mechanisms Underlying the Long-Term Potentiation of GABA Release</u>	2544	Liu, Si-Qiong	Amended	May 25, 2026	Addition of experimental material
<u>miRNA targeting of hypertension and metabolic pathways</u>	7604	Lazartigues, Eric	Amended	September 26, 2029	Change in Personnel
<u>Photoreceptor Degeneration and Neuroprotection</u>	5695	Bazan, Nicolas	Amended	October 19, 2028	Change in Personnel Update in IACUC status or number
<u>RPE Messengers, Transcription and Photoreceptor</u>	2523	Bazan, Nicolas	Amended	August 26, 2026	Change in Personnel

<u>Brain Circuitry in Health and Aging: From Anatomy to Function</u>	9376	Manjila, Steffy	Amended	September 08, 2030	Update in IACUC status or number Change in study location/facilities Update to animal numbers or species
<u>Brain reward and stress system interactions in alcohol dependence</u>	4487	Avegno, Elizabeth	Amended	June 20, 2027	Change in personnel
<u>Regulators of Gustatory Neural Circuitry</u>	4475	Primeaux, Stefany	Amended	June 22, 2027	Change in personnel
<u>Targeting Triple-Negative Breast cancer</u>	7427	Hossain, Fokhrul	Amended	July 22, 2030	Addition of experimental material
<u>Viral Oncology Research Lab – Human Tissues</u>	2470	Wood, Charles	Amended	December 21, 2026	Addition of experimental material
<u>Neuroinflammation in CKD</u>	5653	Mohandas, Rajesh	Amended	August 30, 2028	Addition of experimental material Change in personnel
<u>LSUHSC-NO Comprehensive Alcohol-HIV/AIDS Research Center- Animal Core</u>	2522	Simon Peter, Liz	Amended	August 26, 2026	Change in personnel
<u>Role of heparan sulfate 6-O-endosulfatases in myelopoiesis and myeloid cell function</u>	4970	Yue, Xinping	Amended	February 06, 2028	Change in personnel
<u>Pilot Study of the Effect of Weight Loss by Pharmacotherapy on</u>	5055	Sanchez-Pino, Maria	Close Request		

<u>Chronic Pro-tumor Inflammatory Cells</u>					
<u>Mechanisms that regulate RPE65 isomerase in normal and blindness-associated RPE</u>	4353	Jin, Minghao	Close Request		
<u>Prospective, randomized, split-mouth study evaluating the clinical performance of a new dental adhesive, 3M™ Scotchbond™ Universal Plus Adhesive, compared to 3M™ Scotchbond™ Universal Adhesive when used with 3M™ Filtek™ Universal Restorative to restore Class V non-carious cervical lesions</u>	4349	Yu, Alike	Close Request		
<u>Molecular determinants of parasite fitness in Trypanosoma cruzi</u>	7153	Kelly, Ben	Renewed	April 03, 2029	
<u>Disparities in Orthopaedic Surgical Outcomes: Is there a cellular basis?</u>	2448	Dasa, Vinod	Renewed	February 24, 2027	
<u>Targeting the Renin System for the Treatment of Pain and Opioid Use Disorder</u>	8032	Edwards, Scott	Renewed	January 28, 2030	
<u>Mechanisms and treatment of diuretic resistance</u>	8331	Kapusta, Daniel	Renewed	February 14, 2030	

<u>The role of microRNA in breast cancer</u>	7168	Alahari, Suresh	Renewed	April 03, 2029	
<u>HTR2A Knockout Mouse Breeding (continued)</u>	4866	Nichols, Charles	Renewed	February 06, 2028	
<u>plgR Mice Breeding Colony</u>	8352	Welsh, David	Renewed	March 06, 2030	
<u>Assessing the potential of using ISGylation as a liquid biopsy biomarker for neurodegenerative diseases</u>	8444	Desai, Shyamal	Renewed	March 26, 2030	
<u>Murine Models for Cancer Immunology and Immunotherapy</u>	2469	Ochoa, Augusto	Renewed	December 21, 2027	
<u>Evaluation and Development of 5HT2A receptor agonists as anti-inflammatory therapeutics</u>	4924	Foster, Timothy	Renewed	April 04, 2028	
<u>Effect of NSC compounds on breast cancer cell proliferation and cell migration</u>	7024	Alahari, Suresh	Renewed	March 13, 2029	
<u>High Performance Antimicrobial Fluoride-releasing Dental Materials</u>	5032	Xu, Xiaoming	Renewed	February 15, 2028	
<u>Diagnostic and therapeutic approaches for the treatment of neuroendocrine tumors</u>	5043	Lan, Michael	Renewed	April 04, 2028	

<u>Effects of Upregulating ANKHD1 on Aging and Neuronal Degeneration</u>	4446	Tian, Xiaolin	Renewed	March 31, 2027	
<u>Vascular Smooth Muscle Lysyl Oxidase Mediated Increase in Vessel Stiffness and its Effect on Rho-Kinase Mechanosensors: A Novel Mechanism of Atherosclerosis in Chronic Kidney Disease?</u>	5167	Mohandas, Rajesh	Renewed	May 03, 2028	
<u>Determine the Prevalence of Nontuberculous Mycobacteria Isolation from Showerhead Biofilms in the Greater New Orleans Area and its' Association with Human Pulmonary Disease</u>	2446	Korah-Sedgwick, Michelle	Renewed	March 04, 2027	
<u>Propagation of Glioblastoma cells in immunodeficient and syngeneic mouse models</u>	4351	Reiss, Krzysztof	Renewed	March 30, 2027	
<u>Development of protective vaccine and antibody as Immunotherapies for Disseminated Candidiasis and MDR infections</u>	5011	Xin, Hong	Renewed	January 31, 2028	
<u>Association between epigenetic changes,</u>	8380	Joshi, Vinayak	Renewed	March 18, 2030	

<u>periodontal microbiota, and periodontal inflammation in obese individuals</u>					
<u>Behavioral studies after stroke and traumatic brain injury</u>	4445	Bazan, Nicolas	Renewed/Amended	April 08, 2027	Change in personnel
<u>Interaction of Shisa proteins with GABA(A) receptor function</u>	6694	Winsauer, Peter	Renewed/Amended	February 15, 2029	Change in personnel
<u>Interaction of cannabinoids and opioids on antinociception, learning, and performance behavior</u>	6699	Winsauer, Peter	Renewed/Amended	February 19, 2029	Change in personnel
<u>Use of V.A.C. VERAFLOR to Deliver Pro-Healing and Anti-Infective Agents in an Acute Porcine Model of Surgical Wounds</u>	4915	Smith, Alison	Renewed/Amended	February 06, 2028	Change in personnel
<u>Molecular Profiling and Biomarker Discovery</u>	5033	Adamec, Jiri	Renewed/Amended	February 09, 2028	Change in personnel
<u>"Characterization of Paracrine Factors from Bone Marrow Derived Mesenchymal Stem Cells of Trauma Patients"</u>	2432	Smith, Alison	Renewed/Amended	February 25, 2027	Change in personnel
<u>Studying synaptic development and neurodegeneration using Drosophila fruit flies</u>	8369	Wu, Chunlai	Renewed/Amended	March 11, 2030	Change in personnel

<u>Stanley S. Scott (SSS) Cancer Center Biobank</u>	4989	Moaven, Omeed	Renewed/Amended	January 25, 2028	Change in personnel
<u>Sex differences in metabolism</u>	9716	Wiese, Carrie	Renewed/Amended	September 08, 2030	Change in personnel

- **Applications reviewed and Suspended (in Grace Period) by the Chair after modifications requested by FCR. Continuing IBC oversight is required with annual reviews.**

N/A

- **Full Committee Review of applications subject to *NIH Guidelines and our Policies*. Continuing IBC oversight required.**

	<b>IBC #10410</b>	<b>Oncolytic HSV therapy for cancer</b>
1:35pm	<b>PI Name</b>	Kaur, Balveen
	<b>Project Overview</b>	This project studies a type of cancer treatment called oncolytic viruses, which are designed to selectively infect and destroy cancer cells while leaving normal cells unharmed. These therapies are already approved in some countries for certain cancers, and this research aims to improve their effectiveness. The study will evaluate new versions of these viruses and test them alone or in combination with existing approved drugs to enhance cancer treatment outcomes. Researchers will also investigate how tumors may resist this therapy and identify ways to overcome that resistance. The goal is to support the development of safer and more effective virus-based cancer treatments.
	<b>NIH Guidelines Section(s)</b>	III-D-1-a III-D-2-a III-D-3-a III-F-8 Appx C-VII III-F-8 Appx C-VIII III-F-8
	<b>Risk Assessment &amp; Discussion</b>	Personnel working in the laboratory will use appropriate personal protective equipment (PPE), including gloves, lab coats or disposable gowns, head covers, and surgical masks. All work involving biohazardous materials will be conducted within a certified Class II biosafety cabinet (BSL-2 rated) to ensure proper containment and minimize exposure risk.
	<b>Training</b>	All institutional trainings required are complete for lab staff listed in the registration: <ul style="list-style-type: none"> <li>• COI in Research</li> <li>• Laboratory Safety</li> <li>• IBC Compliance</li> <li>• BBP High Risk</li> </ul>
	<b>EH&amp;S Assessment</b>	The laboratory was inspected, and any identified deficiencies will be addressed prior to the initiation of research activities.

<b>Occupational Health Representative review (if applicable)</b>	N/A
<b>Biosafety Level Assignment</b>	BSL-2 ABSL-1
<b>IACUC status (if applicable)</b>	Application ready for approval
<b>IBC Vote</b>	<p>The Primary Reviewer made a motion to assign the determination of Modifications Required to Secure Approval (MRSA)</p> <ul style="list-style-type: none"> <li>• Votes: 11/11 MRSA</li> <li>• COI: None reported</li> </ul> <p>Following a duly called vote of the committee, Dr. Kaur’s protocol was conditionally approved, pending submission and approval of the requested revisions by the Primary Reviewer.</p>

2:23pm

**Adjournment**

The IBC Chair moved to adjourn the meeting at 2:23PM. The next meeting is tentatively scheduled for Wednesday, April 8, 2025, via Zoom.